Derivatives of 5-Benzylidenehydantoin are well known of their various attractive bioactivities such as anticancer, antimicrobial, antidiabetic and tyrosinase inhibitor. UPR1024 belongs to a new class of EGFR inhibitors characterized by a hydantoin nucleus and a 5-benzylidene substituent having a double bond conjugated with a carbonyl group on the hydantoin ring. The compound had antiproliferative and proapoptotic effects when tested on the non-small cell lung cancer cell line A549[1-2].
5-Benzylidenehydantoins inhibited the EGFR kinase and exhibited an antiproliferative action on A431 human epidermoid carcinoma cells. The conjugated exo-cyclic double bond at the C5 position appeared essential for both EGFR and cell growth inhibition, indicating that the 5-benzylidene hydantoin core would be a suitable scaffold for generating new antiproliferative compounds[3].
[1] Haq, K. U. et al. “Synthesis of 5-benzylidene-hydantoin and 5-benzylidene-creatinine derivatives under mixed catalyst systems of urea-p-toluenesulfonic acid (Urea-PTSA) and guanidine hydrochloride-triethylamine (GnHCl-TEA).”(2020).
[2] Andrea Cavazzoni. “Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.” Molecular Cancer Therapeutics 7 2 (2008): 361–70.
